To effectively manage increased patient volumes and financial demands, healthcare organizations are adopting solutions for electronic patient records and systems that allow them to share patient information in real-time. This segment of e-health is growing, and the growth is expected to accelerate in the coming years. Ortivus is well-positioned to capitalize on this development.

Ortivus shares have been listed on the NASDAQ Stockholm Small Cap-lista since January 2, 1997.

 Stock SymbolISINShares OutstandingVotes/shareTotal Number of Votes
Class AORTI ASE00001889301,662,6821016,626,820
Class BORTI BSE000012308542,644,786 142,644,786

The share capital is SEK 15,507,614. Share capital is divided between class A and class B shares. The number of shares outstanding is 44,307,468 of which class A amount to 1,662,682 and class B to 42,644,786. Every class A share carries 10 votes and every class B share carries one vote.

 

Ortivus A

Ortivus B

Hover the mouse over the graphs to see the share price at the corresponding date.

 

Top 10 Shareholders as per 10th of September 2020

  Number of sharesShare of Capital
PONDERUS INVEST ABSeries A
Series B
Total
13 177
10360762
10373939
23.3%
NORDNET
PENSIONSFÖRSÄKRING A
Series A
Series B
Total
33593
3955703
3989296
9.0%
FÖRSÄKRINGS AB AVANZA
Series A
Series B
Total
54299
3711161
3765460
8.5%
PETTERSSON, RUNESeries B2802620
6.3%
FRAIM, ING-MARIESeries B1974087
4.5%
RASPART FÖRVALTNING ABSeries B1850418
4.2%
ADOLFSSON, PER-OLASeries B1597963
3.6%
SELIGSON & CO PHOENIX FUNDSeries B1554795
3.5%
ERIKSSON, NILS-ARNESeries B1550625
3.5%
GAGAB ABSeries B824659
1.9%
Sum of top 10 shareholders68.4%

 

 

 

 

 

 

Subscribe to Financial Information 

  • Annual General Meeting 2020: 5/5 2021, 16:30-18:00
  • Interim report Q2 2020: 21/08 2020, 08.30 am
  • Interim report Q3 2020: 10/11 2020, 08:30 am
  • Yearend report Q4 2020: 16/2 2021, 08.30 am
  • Interim report Q1 2021: 27/4 2021 kl 08.30
PREVIOUS AG MEETINGS
Ortivus' customer deliveries continue at a high pace despite Covid-19
Read more
Ortivus has successfully completed large deliveries to our British customers during the quarter
Read more
Ortivus AB and SCHILLER AG have decided on a collaboration through a distributor agreement for
Read more
Increase of revenue with 74% compared with previous year first quarter
Read more
Ortivus was, as previous announced, selected last year by the South West Ambulance Service Trust
Read more
ORTIVUS BEFÄSTER LEDANDE POSITION I DEN ENGELSKA AKUTVÅRDSMARKNADEN
Read more
Ortivus AB and Carmenta Public Safety AB strengthen their cooperation by signing a mutual distributor
Read more
Ortivus has been awarded a contract to deliver its pre-hospital MobiMed electronic patient care record
Read more
all Press releases

The board of Ortivus AB (publ) has decided to carry out a 100% secured rights issue of approximately SEK 9 million. The Board’s decision is conditional on the approval of the forthcoming Extraordinary General Meeting, which will be held on February 18, 2019. The proposed pre-emptive share issue intends to improve the Company’s financial position while allowing for continued development of the Company’s operations.

(Documents below are in Swedish only)

  1. Fullmaktsblankett
  2. Styrelseprotokoll
  3. Redogörelse av styrelsen enligt ABL 13-6
  4. Kallelse
  5. Revisorsyttrande
  6. Protokoll extra bolagsstämma i Ortivus

The Board of Directors of Ortivus AB (publ) has, on the basis of authorization from the Annual General Meeting 2019, decided on a new issue comprising 7,500,000 new B shares directed at a small number of specially selected investors. The total share issue raises SEK 15 million before costs for issuing of new shares. The new shares are issued at a subscription price corresponding to SEK 2 per share. The subscription price has been determined on a market basis and corresponds to the volume-weighted price of the company’s B shares during the last 20 trading days with a mark-up of 5%. The investors who signed up for the directed new share issue have undertaken not to sell the newly issued shares within 6 months from the Board’s decision, so-called Lock-up. The rights issue is carried out with the aim of securing further financing of the company’s working capital and the continued development of the company’s operations.

Download the prospectus (in Swedish) “Ortivus-AB-(publ)_Prospekt-avseende-upptagande-till-handel-av-nyemitterade-aktier_2019-07-10” here.